68Ga-P3 PET/CT Imaging in Prostate
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: [68Ga]P3.
- Who it may be relevant to
- Registry conditions: Neoplasms. Basic parameters: 18 years — 75 years · Male.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- China
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Study to Evaluate 68Ga-P3 PET/CT Imaging of PSMA Expression in Prostate
Overview
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies. \[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Detailed description
Prostate-specific membrane antigen (PSMA) is a type II transmembrane glycoprotein that consists of 750 amino acids. It is highly expressed on most prostate cancer cells and neovascular endothelial cells of tumors, making PSMA a highly specific and significant imaging target for malignancies.\[68Ga\]P3, a novel molecular probe of PET imaging agent that targets PSMA, can be used in the diagnosis and research of a wide variety of PSMA high-expression malignanciesr.
Interventions
- Drug [68Ga]P3
68Ga-P3 is injected intravenously with a dose of 0.06-0.08 mCi/kg.
Primary outcome measures
- The diagnostic efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate [Time frame: 1 year]
- The detection efficacy of 68Ga-P3 PET/CT in the evaluation of Prostate [Time frame: 1 year]
Secondary outcome measures (3)
- The dosimetry of 68Ga-P3 [Time frame: 1 year]
- Quantitative evaluation of 68Ga-P3 [Time frame: 1 year]
- Correlation with pathological expression [Time frame: 1 year]
Eligibility criteria
Inclusion criteria
patients with confirmed or suspected cancer; Signed written informed consent
Exclusion criteria
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Allocation
- N/A
- Model
- Single group
- Masking
- Open label
- Primary purpose
- Diagnostic
Study locations
China · 1 center
- Peking University First Hospital — Beijing
Identifiers
NCT: NCT05940259 · [68Ga] P3